What is Creso Pharma Limited (COPHF)?

Creso Pharma Limited (COPHF) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of COPHF?

The current price of COPHF is $0.12. Prices are updated in real time on Stocks360.

What is COPHF's price-to-earnings (PE) ratio?

COPHF's trailing twelve-month PE ratio is 0.00, based on current price and earnings per share data available on Stocks360.

What is COPHF's market capitalization?

COPHF's market capitalization is $131,722,112.00, placing it in the small-cap tier.

Creso Pharma Limited (COPHF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$0.12

Market Cap

$131.72M

PE (TTM)

0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

-24.81

Day Range

$0.00 – $0.12

52-wk Range

$0.00 – $9.47

Avg Volume

N/A

Volume

22.00

Creso Pharma Limited (COPHF) is a publicly traded company in the Healthcare sector. Latest price: $0.12. Market cap $131.72M. Trailing PE 0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

Proprietary Signals

Signal snapshot temporarily unavailable.

About Creso Pharma Limited

Creso Pharma Limited is a global pharmaceutical company focused on the development, registration, and commercialization of advanced cannabis and hemp-based solutions. These therapeutic products and nutraceuticals are designed for both human and animal health applications, with market presence spanning Europe, the Middle East, North America, and the Asia Pacific region. Beyond innovative product creation, the company also manages the cultivation, processing, and distribution of cannabis products, extending its reach to the retail sector. Its diverse portfolio includes specialized offerings such as anibidiol, a complementary nutritional supplement for companion animals. For human wellness, they provide cannaQIX, a nutraceutical blend of hemp oil extract, vitamins, and zinc, formulated to alleviate stress and bolster psychological and neurological functions. The company also manufactures topical and dermatological products, including cannaDOL, a CBD-infused gel combining cooling and warming essential oils. Established in 2015, Creso Pharma Limited maintains its headquarters in Nedlands, Australia.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	0.00×
P/S (TTM)	9.90×
P/B	0.00×
P/FCF (TTM)	-22.17×
EV / EBITDA	-7.80×
EV / Sales	10.38×
Earnings Yield	0.00%
Free Cash Flow Yield	-4.51%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$196.34M
Revenue (TTM)	$18.92M
Net Income (TTM)	$0.00
Free Cash Flow (TTM)	$9.38M
Net Debt	$8.95M
Working Capital	-$17.50M
Gross Margin	12.34%
Operating Margin	-88.16%
Net Margin	-277.18%
Return on Equity	-575.19%
Return on Invested Capital	-298.47%